← Oncology Approval Tracker

FDA DECISION ·

Xtandi

enzalutamide · Astellas Pharma

FDA approvalNew or expanded indicationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For nonmetastatic castration-sensitive prostate cancer with biochemical recurrence and a high risk of metastasis.

LAMPGEN ANALYSIS

Why it matters

The expansion addresses a disease state defined by biochemical recurrence before metastases are detectable.

What research teams should watch

Capture PSA kinetics and staging evidence to distinguish this group from metastatic or castration-resistant populations.

PRIMARY RECORDS

Sources